Cure Parkinson’s and Alzheimer’s Research UK announce a partnership
Cure Parkinson’s and Alzheimer’s Research UK are working on an initiative that could pave the way for innovative neurodegenerative treatments. There is a growing recognition that tackling neurodegenerative diseases could benefit from a collaborative, cross-disease approach. We are recognising the overlap in underlying biological...
Learn more
Could ambroxol help to slow cognitive change in people with Parkinson’s?
The results of a phase 2 clinical trial of ambroxol in Canada for people with Parkinson’s dementia were published recently, finding it was safe and tolerable when taken by participants. A proportion of people with Parkinson’s experience cognitive changes – changes to our memory, thinking,…
New registry Join Parkinson’s Research aims to boost awareness and accessibility of clinical research studies for Parkinson’s
The Join Parkinson’s Research (JPR) registry is a new online platform where people living with the condition can register to hear about the latest clinical studies. Clinical research studies are vital to improve our understanding of Parkinson’s and help develop new treatments. However, due to…
Improving diversity in Parkinson’s research – The East London Parkinson’s Disease Project
The East London Parkinson’s Disease Project (ELPD) is a study led by Professor Alastair Noyce at Queen Mary University London. This Cure Parkinson’s supported initiative seeks to better understand the experiences of people with Parkinson’s from diverse ethnic backgrounds. Recently, the ELPD team published a…
Meet the Researcher: Dr Poonam Thakur on prioritising preclinical research
In this new series from Cure Parkinson’s, we’ll be hearing directly from the scientists putting our funded research projects into action. From learning about their career journeys, to getting an inside look at their studies, we’ll discover how their work aims to support people living…
SLEIPNIR, the new multi-arm clinical trial platform for Parkinson’s treatments
Cure Parkinson’s is excited to announce £1 million in funding for SLEIPNIR – an upcoming multi-arm clinical trial platform in Norway. One of the ongoing challenges for Parkinson’s research is determining whether treatments are reaching the brain and if they are having their intended effect…